Skip to main content

Science Corporation

News

July 22, 2026

Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness

Open full post

The PRIMA retinal implant shown gripped by tweezers

Science Welcomes Nevada Sanchez as Executive Vice President of Engineering

PRIMA Has Received Humanitarian Use Device Designations from the US Food and Drug Administration

Science's Axon Terminal Wins 2026 iF Design Award

Photo of the Axon Terminal

Science Appoints Murat Günel, MD, as Medical Director for Brain-Computer Interfaces

Photo of Dr. Günel.

Expert Opinion: José-Alain Sahel, M.D., on Science’s PRIMA Implant and the ‘Undreamt of’ Progress in Restoring Vision to Clinical Trial Patients

Photo of Dr. Frank Holz.

Science Closes $230 Million Series C to Fund Commercialization of PRIMA BCI Retinal Implant and Expansion of Clinical Trials

February 20, 2026

Science Corp. and Neurosoft Bioelectronics Announce BCI Ecosystem Partnership: Science’s World-Class BCI Systems To Support Neurosoft's Pioneering Neural Data Platform

February 11, 2026

Science Founder and CEO Max Hodak Named to Time 100 Health List of the World’s Most Influential Leaders in Health

February 9, 2026

Expert Opinion: Frank Holz, M.D. on Science’s PRIMA Implant and the New Reality of Restoring Vision to Clinical Trial Patients Who Had Been Functionally Blind

Photo of Dr. Frank Holz.

January 14, 2026

In Editorial, The New England Journal of Medicine Calls Science Corporation's PRIMA Implant 'The First Treatment to Restore Vision' In Patients Suffering From Advanced Geographic Atrophy Due to Age-related Macular Degeneration

Video Library

About Science

Science Corporation develops brain-computer interface (BCI) technology and conducts research on how neural engineering can restore quality of life to patients with debilitating conditions for which there are no treatment options. We are working on creating medical devices aimed at restoring vision, cognition, and mobility, and have dozens of patients in six countries enrolled in our clinical trials.

Contact

For press inquiries, please contact press@science.xyz.

Brand Assets